During a recent webinar, the Department of Health and Human Services (HHS) shared its strategic vision aimed at accelerating the integration of artificial intelligence (AI) within clinical care settings. This initiative is designed to enhance the health of Americans and reduce healthcare expenditures.
HHS officials highlighted key insights from a request for information (RFI) issued late last year, which sought feedback on how the department could leverage its regulatory, research, and reimbursement capabilities to foster AI adoption in healthcare. According to Arman Sharma, the HHS deputy chief AI officer, the healthcare sector has called for better synergy among HHS agencies, guidance in AI implementation and governance, and clarity on effective AI tools. He emphasized, “Establishing trust is essential; it’s what will pave the way for responsible and effective adoption of this technology.”
AI holds great promise for transforming healthcare by streamlining several processes, such as documenting patient care, analyzing health data, assisting providers in research, and generating tailored communications for patients. HHS leaders underscored the importance of AI in expanding the healthcare system's capacity to address the needs of an aging population while also reducing administrative costs and empowering patients in managing their health, potentially alleviating the surge in national health spending.
However, introducing AI into healthcare is fraught with challenges, including risks of inaccurate outputs, biased data, deterioration of models over time, and concerns related to privacy and security. Despite the calls for enhanced federal oversight, the previous administration adopted a nearly deregulatory stance on AI, worrying that stringent regulations might hinder technology development.
Nonetheless, HHS asserts that it has taken significant steps to understand the sector's regulatory needs concerning AI. The RFI released in December was part of this effort to gather input from industry stakeholders, and HHS has since compiled takeaways from hundreds of responses received from health providers, researchers, and professional organizations.
Healthcare entities are specifically asking for actionable guidance on implementing AI and establishing governance frameworks for these technologies. Additionally, they are seeking resources for evaluating and benchmarking AI tools to identify effective solutions, along with a coordinated AI strategy across HHS agencies.
Sharma remarked, “In government, communication gaps can occur, and we cannot afford to let that happen with something as crucial as healthcare AI.”
Moreover, HHS leaders discussed ongoing initiatives to facilitate AI adoption. For instance, the Administration for Community Living recently launched a competition aimed at technology developers focused on creating AI solutions to support caregivers of older adults and individuals with disabilities. The Advanced Research Projects Agency for Health is also engaged in a project centered around developing AI agents for managing cardiovascular care efficiently.
On the regulatory front, Dr. Rick Abramson, director of the FDA’s Digital Health Center of Excellence, noted that the FDA is currently working on policy development related to AI tools but could not disclose specific strategies. However, he outlined several focal points for the FDA’s oversight, such as clarifying its regulatory scope and requirements for developers, establishing regulations that are proportional to the risk associated with AI tools, and harmonizing oversight across a product's entire lifecycle.
Abramson concluded by acknowledging the challenge of keeping pace with rapid technological advancements, stating, “It’s often said that technology evolves on a timescale of weeks to months, while regulation takes months to years. This is a reality that underscores the importance of the FDA’s guidance in navigating advanced clinical AI tools.”
